Moss, 21 March 2024

Due to private reasons the CEO of Gentian Diagnostics ASA, Hilja Ibert, has
decided to resign from her position. Hilja has played a key role in the growth
and success of Gentian Diagnostics ASA since 2018, and her dedication and
contributions to the company over the past years has been outstanding.

However, following the resignation of Hilja Ibert the Nomination Committee is
pleased to recommend her as a candidate for the position of new Chairperson of
the Board. Her wealth of experience and strategic insights will continue to
provide great value for Gentian Diagnostics ASA in this new capacity.

Simultaneously, Tomas Settevik, the Chairperson of the Board, has chosen not to
stand for re-election. Tomas has been instrumental in guiding the board and the
company. We express our thanks for his leadership of the past years.

The Company has initiated a search for Hilja IbertŽs replacement as CEO, in the
meantime Gentian Diagnostics' CFO, Njaal Kind, will serve as the acting CEO.

All the announced changes will take effect as of April 29, 2024, subject to the
approval by the General Meeting.

IR contact: 
Njaal Kind, CFO 
njaal.kind@gentian.no 
+47 919 06 525 (mobile)


This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.